Last reviewed · How we verify
NCT05779514
Effect of Mirabegron on Promoting Brown Adipose Tissue Activation
NA trial testing Mirabegron in Tumour in 20 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Zhejiang Provincial People's Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 18 August 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Mirabegron (MIRABEGRON) — full drug profile →
Conditions studied
- Tumour — all drugs for Tumour →
Sponsor
Zhejiang Provincial People's Hospital
Who can join
Adults 18 to 75, any sex, with Tumour. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In previous preclinical studies, our group found that Mirabegron, a clinical drug, could activate brown adipose tissue and inhibit tumor growth in tumour-bearing mice.Investigators look forward to further evaluating the effect of Mirabegron-mediated brown adipose tissue activation, so as to provide new drug applications for clinical cancer prevention and treatment
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05779514
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mirabegron
Trials testing the same drug.
- NCT05713799 — Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity · Phase 2 · not yet recruiting
- NCT07310797 — Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion · Phase 4 · not yet recruiting
- NCT06534762 — Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study · Phase 2 · recruiting
- NCT06551246 — Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry) · Phase 3 · recruiting
- NCT06465576 — Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry) · Phase 4 · recruiting
Other recruiting trials for Tumour
Currently open trials in the same condition.
- NCT06450145 — Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL · NA · recruiting
Other Zhejiang Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07212634 — Cerebellar Transcranial Direct Current Stimulation for Dysphagia After Supratentorial Stroke · NA · not yet recruiting
- NCT07312422 — LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study · Phase 1, PHASE2 · recruiting
- NCT06975644 — Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) · NA · not yet recruiting
- NCT07068542 — Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05779514 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Provincial People's Hospital
- Last refreshed: 22 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05779514.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing